Abstract
Tyrosine kinase inhibitors (TKIs) of the anaplastic lymphoma kinase gene (ALK) significantly improve quality of life and survival in non-small cell lung cancer (NSCLC) with ALK fusion. However, ALK fusion is extremely rare in small-cell lung cancer (SCLC), and there is no standard treatment at present, and the mechanism of resistance of ALK-TKIs in SCLC is unknown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
